Using MyoScreen™, our human skeletal muscle platform built on primary patient-derived myotubes on micropatterned substrates (100+ mature, standardised myotubes per well of a 96-well plate) here’s what the data showed:
🔹 ALK5 validated as the key upstream driver of myostatin-induced muscle-wasting signals: a new, screenable target
🔹 RepSox, an ALK5 inhibitor, rescued atrophy more potently than bimagrumab (a clinical anti-myostatin antibody) across multiple wasting inducers
🔹 A ~3x increase in glucose uptake in human myotubes : metabolic benefit alongside muscle preservation Human biology. High-content, image-based readouts. Population-level statistical power.
Data your pipeline can act on.
Let’s talk if muscle preservation is on your roadmap, for obesity, sarcopenia, or cachexia !
